Back to results
US 2019/0290637 A1Published application
New phenylpyrazolylacetamide compounds and derivatives as cdk8/cdk19 inhibitors
AssigneeBoehringer Ingelheim International GmbH
InventorsHarald ENGELHARDT, Heribert ARNHOF, Sebastian CAROTTA, Marco Hans HOFMANN, Marc KERENYI, Dirk SCHARN
Life of this patent
Estimating the term…
Abstract
The present invention encompasses compounds of formula (I) wherein the groups R2 to R5, A, X and q have the meanings given in the claims and specification, their use as inhibitors of CDK8/19, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
Claims26
A compound of formula (I)
- wherein
- ring system A is selected from the group consisting of A1 and A2
- R1A is selected from the group consisting of hydrogen, halogen, C1-4alkyl, C1-4haloalkyl, C1-4alkoxy, hydroxy-C1-4alkyl, C1-4alkoxy-C1-4alkyl, —CN and 5-6 membered heteroaryl;
- each R1B is independently selected from the group consisting of hydrogen, halogen, C1-4alkyl, C1-4haloalkyl, C1-4alkoxy, hydroxy-C1-4alkyl, C1-4alkoxy-C1-4alkyl, —CN and 5-6 membered heteroaryl;
- or
- R1A together with R1B and the atoms they are linked to form a 5-6 membered heteroaryl;
- each R2 is independently selected from the group consisting of halogen, C1-4alkyl, C1-4haloalkyl and C1-4alkoxy;
- q has the value 0, 1 or 2;
- Y is CH or N;
- R3 is selected from the group consisting of hydrogen, halogen, C1-4alkyl and C1-4haloalkyl;
- R4 is selected from the group consisting of hydrogen and C1-4alkyl;
- R5 is selected from the group consisting of —NR5AR5B, —OR5C and R5D;
- R5A, R5B and R5C, each independently of one another, denotes hydrogen or a group, optionally substituted by one or more, identical or different Rb1 and/or Rc1, selected from among C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C3-7cycloalkyl, C4-7cycloalkenyl, C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl;
- each Rb1 is independently selected from among —ORc1, —NRc1Rc1, halogen, —CN, —C(O)Rc1, —C(O)ORc1, —C(O)NRc1Rc1, —S(O)2Rc1, —S(O)2NRc1Rc1, —NHC(O)Rc1, —N(C1-4alkyl)C(O)Rc1 and the bivalent substituent ═O, while ═O may only be a substituent in non-aromatic ring systems;
- each Rc1 is independently selected from among hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C3-7cycloalkyl, C4-7cycloalkenyl, C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl;
- or
- R5A together with R4 or R5C together with R4 is C1-5alkylene and R5B is selected from among hydrogen and C1-4alkyl;
- R5D denotes a 3-10 membered nitrogen containing heterocyclyl linked via a nitrogen atom and optionally substituted by one or more, identical or different Rb2 and/or Rc2;
- each Rb2 is independently selected from among —ORc1, —NRc1Rc1, halogen, —CN, —C(O)Rc2, —C(O)ORc2, —C(O)NRc2Rc2, —S(O)2Rc2, —S(O)2NRc2Rc2, —NHC(O)Rc2, —N(C1-4alkyl)C(O)Rc2 and the bivalent substituent ═O;
- each RC2 is independently selected from among hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C3-7cycloalkyl, C4-7cycloalkenyl, C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl;
- or a salt thereof.
18 more elements
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.